Andreea Porcelli cordially Welcomes you back at a pre-holiday Roadshow featuring the "Post Pandemic Recovery Equity SPAC" primary target company Napo EU.

Long-term symptoms are emerging in post COVID long hauler recovery patients [Chronic COVID], that include importantly gastro-intestinal symptoms.

Jaguar Health has developed and commercializes in the US an FDA approved proprietary product for symptomatic relief of long-term gastrointestinal disorders. The company believes the drug may be an effective remedy for Chronic COVID.

The company is planning to study and commercialize this indication with clinical trials in Europe, and its European operation is the target for the Post Pandemic Recover Equity SPAC.

Please see below for a NASDAQ the interview with the CEO Lisa Conte.